Department of Maternal-Fetal Medicine, Ochsner Clinic Foundation, and the Ochsner Clinical School, New Orleans, Louisiana.
Obstet Gynecol. 2023 Mar 1;141(3):555-562. doi: 10.1097/AOG.0000000000005072. Epub 2023 Feb 2.
To compare frequency of perinatal death between pregnant patients who completed the mRNA coronavirus disease 2019 (COVID-19) vaccination series and unvaccinated patients.
This retrospective cohort study included 15,865 pregnant patients who delivered 16,132 newborns after 20 weeks of gestation within a large regional health system between January 1, 2021, and December 31, 2021. Patients who received two doses of mRNA vaccine (Pfizer-BioNTech [BNT162b2] or Moderna [mRNA-1273]) were included in the vaccinated group and were compared with unvaccinated patients. Exclusions included partial vaccination, viral-vector vaccine, major congenital anomalies, and higher-order multiple gestation. Our primary outcome was perinatal death, including stillbirth and neonatal death, which was evaluated by logistic regression. Unadjusted odds ratios and adjusted odds ratios (aORs) were reported, controlling for age, body mass index (BMI), diabetes, hypertension, smoking, twin gestation, and insurance status. Propensity score matching was also performed.
A total of 15,865 patients were included in the final analysis: 2,069 in the vaccination group and 13,796 in the control group. Only 13.0% of the cohort was included in the vaccination group; however, the vaccination rate increased over the course of the study period as the vaccine became more widely available and accepted. Vaccinated patients were older, with higher rates of people of non-Black racial non-Hispanic ethnic backgrounds, people with private insurance, and those with higher BMIs. Vaccination was associated with a lower incidence of perinatal death (0.5% vaccinated group vs 0.8% unvaccinated group, aOR 0.20 0.05-0.88). Vaccination against COVID-19 was also associated with lower rates of preterm delivery (aOR 0.63, 0.48-0.82), neonates with very low birth weight (aOR 0.35, 0.15-0.84), and neonatal intensive care unit (NICU) admission (aOR 0.66, 0.52-0.85). The association between vaccination and lower rates of perinatal death was no longer significant after propensity score matching.
In a large retrospective cohort study, receipt of the primary mRNA COVID-19 vaccination series was associated with a lower rate of several adverse pregnancy outcomes, including perinatal death, preterm delivery, neonates with very low birth weight, and NICU admission. Although the decreased rates of perinatal death did not remain significant after propensity score matching, there was evidence of directional benefit for vaccinated patients.
比较完成 mRNA 冠状病毒病 2019(COVID-19)疫苗接种系列的孕妇与未接种孕妇的围产期死亡率。
本回顾性队列研究纳入了在 2021 年 1 月 1 日至 12 月 31 日期间,在一个大型区域卫生系统内妊娠 20 周后分娩的 15865 名孕妇及其 16132 名新生儿。接受过两剂 mRNA 疫苗(辉瑞-生物技术公司[BNT162b2]或 Moderna [mRNA-1273])的患者被纳入接种组,并与未接种组进行比较。排除标准包括部分接种、病毒载体疫苗、主要先天畸形和多胎妊娠。我们的主要结局是围产期死亡,包括死产和新生儿死亡,通过逻辑回归进行评估。报告了未调整的优势比和调整后的优势比(aOR),控制了年龄、体重指数(BMI)、糖尿病、高血压、吸烟、双胞胎妊娠和保险状况。还进行了倾向评分匹配。
共有 15865 名患者纳入最终分析:接种组 2069 名,对照组 13796 名。只有 13.0%的患者接种了疫苗;然而,随着疫苗的广泛使用和接受,接种率在研究期间有所增加。接种组的患者年龄较大,非裔非西班牙裔背景的人群比例较高,私人保险的人群比例较高,BMI 较高的人群比例较高。接种与围产期死亡发生率较低相关(接种组为 0.5%,未接种组为 0.8%,aOR 0.20[0.05-0.88])。接种 COVID-19 疫苗还与较低的早产率(aOR 0.63[0.48-0.82])、极低出生体重儿(aOR 0.35[0.15-0.84])和新生儿重症监护病房(NICU)入住率(aOR 0.66[0.52-0.85])相关。在进行倾向评分匹配后,接种与较低的围产期死亡率之间的关联不再显著。
在一项大型回顾性队列研究中,接受主要的 mRNA COVID-19 疫苗接种系列与包括围产期死亡在内的多种不良妊娠结局的发生率降低有关,包括早产、极低出生体重儿和新生儿重症监护病房入住率。尽管在进行倾向评分匹配后,围产期死亡率的降低不再显著,但接种组有证据表明存在有利于接种的方向。